Drug intelligence / Profile preview

L-OptiZinc

Development stage: Unknown
Lead developer: Lonza
Modality: Small Molecules
Administration: Oral

Overview

L-OptiZinc is a patented dietary supplement ingredient consisting of zinc mono-L-methionine sulfate, a chelated form of zinc complexed with the amino acid L-methionine in a 1:1 ratio. Developed by Lonza (formerly InterHealth Nutraceuticals), it is designed to provide superior bioavailability and longer retention in the body compared to other forms of zinc. As an essential mineral, zinc serves as a cofactor for over 300 enzymes and plays a critical role in immune function, DNA synthesis, and antioxidant defense. L-OptiZinc is primarily marketed for general health support, including immune system enhancement and protection against oxidative stress.

Brand names: L-OptiZinc
Other names: zinc mono-L-methionine sulfatezinc methionine

Beyond the preview

Go deeper on L-OptiZinc.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L-OptiZinc.

Explore the full profile